Genistein represses PEPCK-C expression in an insulin-independent manner in HepG2 cells and in alloxan-induced diabetic mice

Journal of Cellular Biochemistry

Volumn 119, Issue 2, 2018, Pages 1953-1970

  Dkhar, Barilin ^a   Khongsti, Kitboklang ^a   Thabah, Daiahun ^a   Syiem, Donkupar ^a   Satyamoorthy, Kapaettu ^b   Das, Bidyadhar ^a  

^a NORTH EASTERN HILL UNIVERSITY   (India)

^b MANIPAL SCHOOL OF LIFE SCIENCES   (India)

Author keywords

AMPK PKB Akt MEK ERK pathways; genistein; PEPCK C; T2DM

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DEXAMETHASONE; GENISTEIN; GLUCOSE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); ALLOXAN; INSULIN; PCK2 PROTEIN, HUMAN; PHOSPHOENOLPYRUVATE CARBOXYKINASE (ATP);

ALLOXAN-INDUCED DIABETES MELLITUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; GLYCOGEN ANALYSIS; HEP-G2 CELL LINE; HYPERGLYCEMIA; LIVER METABOLISM; MALE; MAPK SIGNALING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; WEIGHT REDUCTION; WESTERN BLOTTING; ANIMAL; DOWN REGULATION; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; SIGNAL TRANSDUCTION;

ALLOXAN; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DOWN-REGULATION; GENE EXPRESSION REGULATION; GENISTEIN; GLUCOSE; HEP G2 CELLS; HUMANS; INSULIN; MICE; PHOSPHOENOLPYRUVATE CARBOXYKINASE (ATP); SIGNAL TRANSDUCTION;

EID: 85033599912     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.26356     Document Type: Article

References (68)

1. Consoli A, Nurjhan N. Contribution of gluconeogenesis to overall glucose output in diabetic and nondiabetic men. Ann Med. 1990; 22:191–195.
2. Perriello G, Pampanelli S, Del Sindaco P, et al. Evidence of increased systemic glucose production and gluconeogenesis in an early stage of NIDDM. Diabetes. 1997; 46:1010–1016.
3. Rognstad R. Rate-limiting steps in metabolic pathways. J Biol Chem. 1979; 254:1875–1878.
4. Hanson RW, Reshef L. Regulation of phosphoenolpyruvate carboxykinase (GTP) gene expression. Annu Rev Biochem. 1997; 66:581–611.
5. Veneziale CM, Donofrio JC, Nishimura H. The concentration of P-enolpyruvate carboxykinase protein in murine tissues in diabetes of chemical and genetic origin. J Biol Chem. 1983; 258:14257–14262.
6. Nandan SD, Beale EG. Regulation of phosphoenolpyruvate carboxykinase mRNA in mouse liver, kidney and fat tissues by fasting, diabetes and insulin. Lab Anim Sci. 1992; 42:473–477.
7. Valera A, Pujol A, Pelegrin M, Bosch F. Transgenic mice overexpressing phosphoenolpyruvate carboxykinase develop non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA. 1994; 91:9151–9154.
8. Sun Y, Liu S, Ferguson S, et al. Phosphoenolpyruvate carboxykinase overexpression selectively attenuates insulin signaling and hepatic insulin sensitivity in transgenic mice. J Biol Chem. 2002; 277:23301–23307.
9. Gomez-Valades AG, Vidal-Alabró A, Molas M, et al. Overcoming diabetes-induced hyperglycemia through inhibition of hepatic phosphoenolpyruvate carboxykinase (GTP) with RNAi. Mol Ther. 2006; 13:401–410.
10. Gomez-Valades AG, Méndez-Lucas A, Vidal-Alabró A, et al. Pck1 gene silencing in the liver improves glycemia control, insulin sensitivity, and dyslipidemia in db/db mice. Diabetes. 2008; 57:2199–2210.
11. She P, Burgess SC, Shiota M, et al. Mechanisms by which liver-specific PEPCK knockout mice preserve euglycemia during starvation. Diabetes. 2003; 52:1649–1654.
12. Sasaki K, Cripe TP, Koch SR, et al. Multihormonal regulation of phosphoenolpyruvate carboxykinase gene transcription. The dominant role of insulin. J Biol Chem. 1984; 259:15242–15251.
13. Herzig S, Long F, Jhala US, et al. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature. 2001; 413:179–183.
14. Hall RK, Yamasaki T, Kucera T, Waltner-Law M, O'Brien R, Granner DK. Regulation of phosphoenolpyruvate carboxykinase and insulin-like growth factor-binding protein-1 gene expression by insulin. The role of winged HELIX/FORKHEAD proteins. J Biol Chem. 2000; 275:30169–30175.
15. Yadav H, Devalaraja S, Chung ST, Rane SG. TGF-ß1/Smad3 pathway targets PP2A-AMPK-FoxO1 signaling to regulate hepatic gluconeogenesis. J Biol Chem. 2017; 292:3420–3432.
16. He L, Sabet A, Djedjos S, et al. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell. 2009; 137:635–646.
17. Koo SH, Flechner L, Qi L, et al. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature. 2005; 437:1109–1111.
18. Seo WD, Lee JH, Jia Y, Wu C, Lee SJ. Saponarin activates AMPK in a calcium-dependent manner and suppresses gluconeogenesis and increases glucose uptake via phosphorylation of CRTC2 and HDAC5. Bioorg Med Chem Lett. 2015; 25:5237–5242.
19. Yoon JC, Puigserver P, Chen G, et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature. 2001; 413:131–138.
20. Qiu S, Vazquez JT, Boulger E, et al. Hepatic estrogen receptor α is critical for regulation of gluconeogenesis and lipid metabolism in males. Sci Rep. 2017; 7:1661. https://doi.org/10.1038/s41598-017-01937-4.
21. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005; 1:15–25.
22. Horike N, Sakoda H, Kushiyama A, et al. AMP-activated protein kinase activation increases phosphorylation of glycogen synthase kinase 3β and thereby reduces cAMP-responsive element transcriptional activity and phosphoenolpyruvate carboxykinase C gene expression in the liver. J Biol Chem. 2008; 283:33902–33910.
23. Fryer LG, Parbu-Patel A, Carling D. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem. 2002; 277:25226–25232.
24. Atteritano M, Marini H, Minutoli L, et al. Effects of the phytoestrogen genistein on some predictors of cardiovascular risk in osteopenic, postmenopausal women: a two-year randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2007; 92:3068–3075.
25. Choi MS, Jung UJ, Yeo J, Kim MJ, Lee MK. Genistein and daidzein prevent diabetes onset by elevating insulin level and altering hepatic gluconeogenic and lipogenic enzyme activities in non-obese diabetic (NOD) mice. Diabetes Metab Res Rev. 2008; 24:74–81.
26. Fu Z, Gilbert ER, Pfeiffer L, Zhang Y, Fu Y, Liu D. Genistein ameliorates hyperglycemia in a mouse model of nongenetic type 2 diabetes. Appl Physiol Nutr Metab. 2012; 37:480–488.
27. Mezei O, Banz WJ, Steger RW, Peluso MR, Winters TA, Shay N. Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR pathways in obese Zucker rats and murine RAW 264.7 cells. J Nutr. 2003; 133:1238–1243.
28. Davis J, Higginbotham A, O'Connor T, et al. Soy protein and isoflavones influence adiposity and development of metabolic syndrome in the obese male ZDF rat. Ann Nutr Metab. 2007; 51:42–52.
29. Arunkumar E, Anuradha CV. Genistein promotes insulin action through adenosine monophosphate-activated protein kinase activation and p70 ribosomal protein S6 kinase 1 inhibition in the skeletal muscle of mice fed a high energy diet. Nutr Res. 2012; 32:617–625.
30. Seenappa V, Das B, Joshi MB, Satyamoorthy K. Context dependent regulation of human phosphoenolpyruvate carboxykinase isoforms by DNA promoter methylation and RNA stability. J Cell Biochem. 2016; 117:2506–2520.
31. Ding M, Pan A, Manson JE, et al. Consumption of soy foods and isoflavones and risk of type 2 diabetes: a pooled analysis of three US cohorts. Eur J Clin Nutr. 2016; 70:1381–1387. https://doi.org/10.1038/ejcn.2016.117
32. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65:55–63.
33. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970; 227:680–685.
34. Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem. 1976; 72:248–254.
35. Kuo MH, Allis CD. In vivo cross-linking and immunoprecipitation for studying dynamic protein: DNA associations in a chromatin environment. Methods. 1999; 19:425–433.
36. Johnson TA, Holyoak T. The Ω-loop lid domain of phosphoenolpyruvate carboxykinase is essential for catalytic function. Biochemistry. 2012; 51:9547–9559.
37. Reitman S, Frankel S. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol. 1957; 28:56–63.
38. Seifter S, Dayton S, Novic B, Muntwyler E. The estimation of glycogen with the anthrone reagent. Arch Biochem. 1950; 25:191–200.
39. Agati JM, Yeagley D, Quinn PG. Assessment of the roles of mitogen-activated protein kinase, phosphatidylinositol 3-kinase, protein kinase B, and protein kinase C in insulin inhibition of cAMP induced phosphoenolpyruvate carboxykinase gene transcription. J Biol Chem. 1998; 273:18751–18759.
40. Liao J, Barthel A, Nakatani K, Roth RA. Activation of protein kinase B/Akt is sufficient to repress the glucocorticoid and cAMP induction of phosphoenolpyruvate carboxykinase gene. J Biol Chem. 1998; 273:27320–27324.
41. Bhathena SJ, Velasquez MT. Beneficial role of dietary phytoestrogens in obesity and diabetes. Am J Clin Nutr. 2002; 76:1191–1201.
42. Park SA, Choi MS, Cho SY, et al. Genistein and daidzein modulate hepatic glucose and lipid regulating enzyme activities in C57BL/KsJdb/ db mice. Life Sci. 2006; 79:1207–1213.
43. Cheong SH, Furuhashi K, Ito K, et al. Antihyperglycemic effect of equol, a daidzein derivative, in cultured L6 myocytes and ob/ob mice. Mol Nutr Food Res. 2014a; 58:267–277.
44. Cheong SH, Furuhashi K, Ito K, et al. Daidzein promotes glucose uptake through glucose transporter 4 translocation to plasma membrane in L6 myocytes and improves glucose homeostasis in type 2 diabetic model mice. J Nutr Biochem. 2014b; 25:136–143.
45. Ørgaard A, Jensen L. The effects of soy isoflavones on obesity. Exp Biol Med. 2008; 233:1066–1080.
46. Yang W, Wang S, Li L, Liang Z, Wang L. Genistein reduces hyperglycemia and islet cell loss in a high-dosage manner in rats with alloxan-induced pancreatic damage. Pancreas. 2011; 40:396–402.
47. Talaei M, Pan A. Role of phytoestrogens in prevention and management of type 2 diabetes. World J Diabetes. 2015; 6:271–283.
48. Sutherland C, O'Brien RM, Granner DK. Phosphatidylinositol 3-kinase, but not p70/p85 ribosomal S6 protein kinase, is required for the regulation of phosphoenolpyruvate carboxykinase gene expression by insulin. J Biol Chem. 1995; 270:15501–15506.
49. Arunkumar E, Karthik D, Anuradha CV. Genistein sensitizes hepatic insulin signaling and modulates lipid regulatory genes through p70 ribosomal S6 kinase-1 inhibition in high-fat-high-fructose diet-fed mice. Pharm Biol. 2013; 51:815–824.
50. Wang M, Gao XJ, Zhao WW, Zhao WJ, Jiang CH, Huang F. Opposite effects of genistein on the regulation of insulin-mediated glucose homeostasis in adipose tissue. Br J Pharmacol. 2013; 170:328–340.
51. Biggs WH, Meisenhelder J, Hunter T, Cavenee WK, Arden KC. Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci USA. 1999; 96:7421–7426.
52. Lu M, Wan M, Leavens KF, et al. Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1. Nat Med. 2012; 18:388–395.
53. Cheng Z, White MF. Targeting Forkhead box O1 from the concept to metabolic diseases: lessons from mouse models. Antioxid Redox Signal. 2011; 14:649–661.
54. Cederroth CR, Vinciguerra M, Gjinovci A, et al. Dietary phytoestrogens activate AMP-activated protein kinase with improvement in lipid and glucose metabolism. Diabetes 2008; 57:1176–1185.
55. Kim MH, Kang KS, Lee YS. The inhibitory effect of genistein on hepatic steatosis is linked to visceral adipocyte metabolism in mice with diet-induced non-alcoholic fatty liver disease. Br J Nutr. 2010a; 104:1333–1342.
56. Lochhead PA, Salt IP, Walker KS, Hardie DG, Sutherland C. 5-aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase. Diabetes. 2000; 49:896–903.
57. Kim SJ, Yuan HD, Chung SH. Ginsenoside Rg1 suppresses hepatic glucose production via AMP-activated protein kinase in HepG2 cells. Biol Pharm Bull. 2010b; 33:325–328.
58. Yuan HD, Piao GC. An active part of Artemisia sacrorum Ledeb. suppresses gluconeogenesis through AMPK mediated GSK3β and CREB phosphorylation in human HepG2 cells. Biosci Biotechnol Biochem. 2011; 75:1079–1084.
59. Zhang M, Lv X, Li J, et al. Sodium caprate augments the hypoglycemic effect of berberine via AMPK in inhibiting hepatic gluconeogenesis. Mol Cell Endocrinol. 2012; 363:122–130.
60. Guo L, Zheng X, Liu J, Yin Z. Geniposide suppresses hepatic glucose production via AMPK in HepG2 cells. Biol Pharm Bull. 2016; 39:484–491.
61. Gabbay RA, Sutherland C, Gnudi L, et al. Insulin regulation of phosphoenolpyruvate carboxykinase gene expression does not require activation of the Ras/mitogen-activated protein kinase signaling pathway. J Biol Chem. 1996; 271:1890–1897.
62. Sutherland C, Waltner-Law M, Gnudi L, Kahn BB, Granner DK. Activation of the ras mitogen-activated protein kinase-ribosomal protein kinase pathway is not required for the repression of phosphoenolpyruvate carboxykinase gene transcription by insulin. J Biol Chem. 1998; 273:3198–3204.
63. Banks AS, McAllister FE, Camporez JPG, et al. An ERK/Cdk5 axis controls the diabetogenic actions of PPARγ. Nature. 2015; 517:391–395.
64. Jiao P, Feng B, Li Y, He Q, Xu H. Hepatic ERK activity plays a role in energy metabolism. Mol Cell Endocrino. 2013; 375:157–166.
65. Feng B, Jiao P, Yang Z, Xu H. MEK/ERK pathway mediates insulin promoted degradation of MKP-3 protein in liver cells. Mol Cell Endocrinol. 2012; 361:116–123.
66. Xu H, Yang Q, Shen M, Huang X, Dembski M, Gimeno R. Dual specificity MAPK phosphatase 3 activates PEPCK gene transcription and increases gluconeogenesis in rat hepatoma cells. J Biol Chem. 2005; 280:36013–360188.
67. Barthel A, Schmoll D, Kruger KD, Roth RA, Joost HG. Regulation of the forkhead transcription factor FKHR (FOXO1a) by glucose starvation and AICAR, an activator of AMP-activated protein kinase. Endocrinology. 2002; 143:3183–3186.
68. Sajan MP, Bandyopadhyay G, Miura A, et al. AICAR and metformin, but not exercise, increase muscle glucose transport through AMPK-, ERK-, and PDK1-dependent activation of atypical PKC. Am J Physiol Endocrinol Metab. 2010; 298:E179.